Utilizing a murine model of S. pneumoniae infection and restraint stress, we determined how corticotropin releasing hormone (CRH-R) receptors impacts disease. CRH-R1 (antalarmin) and CRH-R2 (astressin2B) antagonists were administered intraperitoneally prior to restraint stress followed by pulmonary S. pneumoniae infection. CRH-R1 inhibition is not protective against pneumococcal disease induced by stress. Conversely, CRH-R2 inhibition attenuates stress-induced bacterial growth and significantly prevented severe sepsis. Neutrophillic responses were associated with CRH receptor-specific disease outcome providing a potential cellular target for stress-induced susceptibility to the development of severe pneumococcal disease. CRH receptor-mediated effects on immune responses could prove valuable for novel therapeutics.
Introduction
Mal-adaptation to external and perceived threats considered life stressors are considered to impact the susceptibility and severity of disease states including: infectious disease and non-infectious chronic disease (Cohen et al., 1991; Glaser et al., 1992; Vedhara et al., 1999; Joachim et al., 2003; Deshmukh et al., 2010) . Because immune function is central to the resolution and progression of disease states, interactions between the immune and central nervous systems are proposed to be a defining link, which explains the role of stress on disease outcomes. The central nervous system (CNS) influences immune function directly by the responsiveness of immune cells' expression of receptors specific for neuroendocrine response elements (Glaser and Kiecolt-Glaser, 2005; Godbout and Glaser, 2006) . In addition, communication between CNS and immune responses is transmitted indirectly through nervous system innervations of major lymphoid tissues and peripheral organs (Hall and Humbertson, 1968; Felten et al., 1981 Felten et al., , 1987 . Importantly, the resultant of such interactions on immunity is very diverse. Both in humans and experimental animal models, the consequences of neuro-hormone and neurotransmitter activation are found to suppress as well as elevate immune responses, depending on individual characteristics (e.g. genetic, perception) and/or environmental factors (e.g. type or quality of the stressor) (Cohen et al., 1993; Gonzalez-Gay et al., 2003; Ziaian et al., 2006; Gonzales et al., 2008; Turyk et al., 2008; Wang et al., 2008; Bailey et al., 2009; Kimura et al., 2009; Schwabe et al., 2009; Deshmukh et al., 2010; Heffner, 2011) . Elevations in glucocorticoids for example, have been shown to suppress cell-mediated immune responses resulting in susceptibility to infectious and non-infectious disease states (Ferrari, 2003; Schwabe et al., 2009; Solodushko et al., 2009; Elftman et al., 2010; Smets et al., 2010; Sommershof et al., 2011) . In contrast, stress-induced activation of sympathetic nervous system pathways has been shown to provoke heighted immune responses, resulting in immune-mediated pathogenesis (Chen and Miller, 2007; Bhowmick et al., 2009; Meyer et al., 2009; Perez et al., 2009 ). Such divergent effects on immune function underscore a need to further investigate the mechanistic pathways involved in neuroimmune interactions as a basis for disease.
Corticotropin releasing hormone (CRH) is a 41-amino acid peptide primarily produced in the hypothalamus and brain regions (Vale et al., 1981) , where it plays an important role in behavioral and autonomic responses to stress (Orth, 1992; Heinrichs et al., 1993 ). CRH's common influence on immune function is primarily thought to be the activation of corticosteroid-mediated pathways, which typically suppresses immune function. There is however, increasing evidence that CRH is also expressed at local sites of inflammation, suggesting its role in disease pathogenesis (Webster et al., 1996; Kalantaridou et al., 2007; Gonzales et al., 2008; Tache et al., 2009; Wallon and Soderholm, 2009 ). In particular, previous studies have documented CRH Journal of Neuroimmunology 237 (2011) 57-65 
